Clinical trials: Kidney Neoplasms
Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
A pilot study evaluating baseline and on-treatment changes in tumor fraction (TFx) in peripheral blood in patients with NSCLC and RCC being treated with checkpoint inhibitor therapy as part of standard of care.
- Trial name
- NCT06630429
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Renal Cell Carcinoma
Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study.
RCC represents around 3% of all cancers, with the highest incidence occurring in Western countries . Within the several RCC risk factors identified, smoking, obesity, and hypertension are most strongly associated with RCC .
- Trial name
- NCT05486871
- Testing
- laparoscopic partial nephrectomy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Prostate Cancer, Urologic Cancer
The Man Van Project
National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care…
- Conditions
- Prostate Cancer, Urologic Cancer, Urologic Diseases, Bladder Cancer
- Trial name
- MV (NCT06357416)
- Testing
- MV-POCT Sub-study, Main Man Van Group Sub-study (MV-Eco), MV-QualQ Sub-study
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Stage II Breast Cancer, Stage III Breast Cancer
Ask Questions (ASQ):Implementation of a Communication Intervention
This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting.
- Conditions
- Stage II Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage II Colorectal Cancer
- Trial name
- NCT05025748
- Testing
- Behavioral Intervention
- Where
- 8 sites in United States
- Volunteers
- 81 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Renal Cell Carcinoma
T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY)
To define the frequency of T regulatory cells in peripheral blood of RCC patients before and after nephrectomy. Study hypothesis: That nephrectomy results in a normalisation of peripheral blood T regs in early stage RCC, and a…
- Trial name
- NCT00717743
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Chemotherapeutic Agent Toxicity, Renal Toxicity
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Chemotherapeutic Agent Toxicity, Renal Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00695032
- Testing
- cisplatin, ifosfamide, laboratory biomarker analysis
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Claudius Regaud
Renal Cell Carcinoma
Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
The purpose of the proposed trial is to determine whether contrast-enhanced ultrasound (CEUS) can be used to assess the recurrence of renal cell carcinoma (RCC) after cryoablation compared to contrast enhanced CT or MR (the…
- Trial name
- NCT02440334
- Testing
- Optison
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Thomas Jefferson University
Skin Cancer, Kidney Transplant Recipients
Pilot Trial of Supplemental Vitamin A and Nicotinamide
The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 [niacin]) and vitamin A in a high-risk population of kidney transplant recipients with a history of…
- Trial name
- NCT05702398
- Testing
- Vitamin A, Nicotinamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rhode Island Hospital
Cystic Renal Disease, Kidney Cancer
Comparison of Surgery and Active Surveillance in the Treatment of Bosniak III Renal Cysts
The incidence of renal cysts is rising due to increased abdominal imaging. Renal complicated cysts have been traditionally classified according to the Bosniak classification, which distinguishes cystic masses by specific features…
- Conditions
- Cystic Renal Disease, Kidney Cancer, Surgery
- Trial name
- NCT04670887
- Testing
- Delayed surgery, Immediate surgery
- Volunteers
- 200 people
- Sponsor
- Helsinki University Central Hospital
Neoplasms
Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate (MTX) clearance owing to MTX-induced renal failure following high-dose MTX therapy, or with intrathecal MTX overdose.
- Trial name
- NCT00219791
- Testing
- glucarpidase (50 Units/kg)
- Where
- Germany
- Sponsor
- BTG International Inc.
Hyperparathyroidism; Secondary, Renal
Preemptive and Precise Intervention for CKD-SHPT
Through multi-center randomized controlled trial studies on preemptive surgical intervention in patients with chronic kidney disease (CKD) - secondary hyperparathyroidism (SHPT), to precisely evaluate the safety and effectiveness…
- Trial name
- NCT04523974
- Testing
- Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Clear Cell Renal Cell Carcinoma
Diagnostic Imaging for Clear Cell Renal Cell Carcinoma
The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.
- Trial name
- RCCSCAN (NCT03185182)
- Testing
- Ioflupane I123
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Region Skane
Advanced Kidney Cancer, Kidney Cancer
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib/II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose…
- Conditions
- Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT03308396
- Testing
- Guadecitabine, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Ajjai Alva, MD
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded…
- Trial name
- NCT04195750
- Testing
- Belzutifan, Everolimus
- Where
- 172 sites in United States, Brazil and 21 more
- Volunteers
- 755 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer)
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer
- Trial name
- NEUTROFLOW (NCT07246759)
- Testing
- Blood sample collection
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- OncoHost Ltd.
Carcinoma, Renal Cell
KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers
Kidney cancer is a highly malignant disease with 950 new cases every year in Denmark. Diagnosis and treatment of kidney cancer patients presents many challenges because that early stages of the disease are often asymptomatic and…
- Trial name
- NCT04295174
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Odense University Hospital
Kidney Cancer, Melanoma (Skin)
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00462982
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with severe renal impairment when compared to the Control group (cancer subjects with normal or mildly impaired renal function)
- Trial name
- NCT01853046
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 9 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Bayer